ABIOMED (NASDAQ:ABMD) had its target price hoisted by Jefferies Group to $250.00 in a research note published on Friday morning, The Fly reports. They currently have a buy rating on the medical equipment provider’s stock.
ABMD has been the subject of a number of other research reports. Zacks Investment Research raised shares of ABIOMED from a hold rating to a buy rating and set a $220.00 price objective for the company in a report on Tuesday, November 7th. BidaskClub raised shares of ABIOMED from a hold rating to a buy rating in a report on Thursday, January 11th. Piper Jaffray Companies upped their price target on shares of ABIOMED to $200.00 and gave the stock an overweight rating in a report on Thursday, October 26th. BTIG Research reaffirmed a hold rating on shares of ABIOMED in a report on Sunday, October 29th. Finally, SunTrust Banks reaffirmed a buy rating and set a $195.00 price target on shares of ABIOMED in a report on Wednesday, November 1st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $199.67.
Shares of ABIOMED (ABMD) opened at $215.11 on Friday. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The stock has a market cap of $9,511.33, a PE ratio of 105.97, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15. ABIOMED has a twelve month low of $103.53 and a twelve month high of $216.15.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.16. The firm had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.20 EPS. equities research analysts expect that ABIOMED will post 2.41 earnings per share for the current fiscal year.
In other news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the sale, the vice president now owns 56,757 shares of the company’s stock, valued at approximately $10,139,070.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now directly owns 39,532 shares of the company’s stock, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in ABIOMED by 3.2% in the 2nd quarter. BlackRock Inc. now owns 3,373,655 shares of the medical equipment provider’s stock valued at $483,444,000 after purchasing an additional 103,410 shares during the last quarter. Vanguard Group Inc. lifted its stake in ABIOMED by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,317,593 shares of the medical equipment provider’s stock valued at $475,411,000 after purchasing an additional 51,055 shares during the last quarter. Baillie Gifford & Co. lifted its stake in ABIOMED by 0.3% in the 3rd quarter. Baillie Gifford & Co. now owns 1,976,961 shares of the medical equipment provider’s stock valued at $333,316,000 after purchasing an additional 5,271 shares during the last quarter. Palo Alto Investors LLC lifted its stake in ABIOMED by 1.6% in the 2nd quarter. Palo Alto Investors LLC now owns 1,951,284 shares of the medical equipment provider’s stock valued at $279,619,000 after purchasing an additional 29,800 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in ABIOMED by 102.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock valued at $181,553,000 after purchasing an additional 543,793 shares during the last quarter. 90.75% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/16/abiomed-abmd-pt-raised-to-250-00-at-jefferies-group.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.